Conclusions
Using a modified Delphi technique, we have defined a patient cohort with CRSwNP where the BRS Council believe use of biologics are appropriate. This group have higher rates of ‘failure’ with current treatment pathways, higher resource use and are more likely to suffer with uncontrolled symptoms. We would urge NICE to consider approval of biologics for such indications without applying further restrictions on use.
Ethical approval
There was no need for ethical approval for this study
Data availability
The results of scoring of the Delphi round may be made available to the editorial team on request but it is not common practice to publish the scores alongside the recommendations.